Reviewing Clinuvel Pharmaceuticals (OTCMKTS:CLVLY) & Nintendo (OTCMKTS:NTDOY)

Nintendo (OTCMKTS:NTDOY) and Clinuvel Pharmaceuticals (OTCMKTS:CLVLY) are both consumer discretionary companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nintendo and Clinuvel Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nintendo	1	4	3	1	2.44
Clinuvel Pharmaceuticals	0	0	0	0	0.00

Valuation & Earnings

This table compares Nintendo and Clinuvel Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nintendo	$15.37 billion	4.68	$2.80 billion	$0.66	21.17
Clinuvel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Nintendo has higher revenue and earnings than Clinuvel Pharmaceuticals.

Profitability

This table compares Nintendo and Clinuvel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nintendo	21.00%	16.11%	12.47%
Clinuvel Pharmaceuticals	N/A	N/A	N/A

Insider and Institutional Ownership

0.0% of Nintendo shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Nintendo beats Clinuvel Pharmaceuticals on 8 of the 8 factors compared between the two stocks.

About Nintendo

Nintendo Co., Ltd., together with its subsidiaries, develops, manufactures, and sells home entertainment products in Japan, the Americas, Europe, and internationally. It also offers video game platforms, playing cards, Karuta, and other products; and handheld and home console hardware systems and related software. The company was formerly known as Nintendo Playing Card Co., Ltd. and changed its name to Nintendo Co., Ltd. in 1963. Nintendo Co., Ltd. was founded in 1889 and is headquartered in Kyoto, Japan.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.